NTN. V. Tsentr

N. V. Tsentr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


N. V. Tsentr has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PET/CT in topical diagnostics of recurrent medullary thyroid cancer: which radiopharmaceutical is preferred?

    by N. V. Tsentr, D. V. Ryzhkova

    Introduction. Medullary thyroid cancer (MTC) is characterized by a high risk of recurrence in the postoperative period, for the topographic localization of which, standard imaging methods are not sufficiently effective. Determination of the level of calcitonin and CEA is key test for monitoring the appearance of recurrent tumor foci, but does not indicate their localization. Based on the accumulated global experience, it has been established that the most promising methods for determining local recurrence and localization of metastases of MTC are PET/CT with [18F]-DOPA and [68Ga]-DOTA-peptides, however, data on their comparative effectiveness remain controversial. The objective was to perform an analytical comparison of the diagnostic capabilities of PET/CT with [18F]-DOPA and [68Ga]-DOTA-peptides for the topographic diagnosis of recurrent foci and assessment of the tumor burden in biochemical recurrence of MTC. Methods and materials. A retrospective analysis of studies of 100 patients with biochemical recurrence of MTC (calcitonin level> 10 pg/ml) who underwent PET/CT with [68Ga]-DOTA-peptides and/or with [18F]-DOPA, including the study of 31 patients with both radiopharmaceuticals. The analysis included an assessment of the number, localization and intensity of the accumulation foci of radiopharmaceuticals, an assessment of the correlation of the basal serum calcitonin level and the results of PET/CT. Results . In 67 out of 100 patients (67%), recurrent foci were detected using PET/CT. Direct comparison of PET/CT scans with [68Ga]-DOTA-peptides and [18F]-DOPA in 31 patients did not show any statistically significant differences in the number of lesions detected between the two radiopharmaceuticals (Wilcoxon – 1.667, p=0.096). However, in some cases, discordant results were observed: in 2 patients, [18F]-DOPA revealed more foci (in the lymph nodes, liver, and bones), and in 1 patient, [68Ga]-DOTA-peptides showed significantly higher contrast of the foci. With serum basal calcitonin values below 150 pg/ml, tumor foci were detected in almost half of PET/CT patients with both [18F]-DOPA (45 %) and [68Ga]-DOT peptides (42 %). There was only a moderate positive correlation between the level of the cancer marker and the number of detected foci (Spearman 0.47 and 0.35, for [18F]-DOPA and [68Ga]-DOT peptides, respectively, pConclusion. PET/CT with [18F]-DOPA and with [68Ga]-DOTA-peptides are highly informative for the topographic diagnosis of recurrent tumor foci in MTC with comparable diagnostic efficiency. In cases of common forms of MTC, it is preferable to perform a comprehensive PET/CT scan using both radiopharmaceuticals, which will ensure maximum diagnostic accuracy and determine the future strategy of personalized treatment.

  • Open Access

    Optimization of [18F]-DOPA PET/CT Protocol in Patients with Medullary Thyroid Carcinoma: a Prospective Study

    by N. V. Tsentr, D. V. Ryzhkova

    Introduction. The method of positron emission tomography combined with X-ray computed tomography (PET/CT) with [18F]-L-dihydroxyphenylalanine ([18F]-DOPA) is the most accurate technique in the detection of tumor tissue in the patients with biochemical relapse of medullary thyroid carcinoma. According to foreign recommendations, the optimal time to [18F]-DOPA PET/CT scanning begin is considered to be an interval of 30–60 minutes after injection of the radiopharmaceutical. However, there are limited publications with a small group of patients that have demonstrated increased sensitivity of [18F]-DOPA PET/CT when scanning was started 15–20 minutes after tracer administration.The objective was to improve the [18F]-DOPA PET/CT study protocol in patients with biochemical relapse of medullary thyroid carcinoma by selecting the optimal time to the start of PET/CT scanning after injection of the radiopharmaceutical.Methods and materials. We analyzed the data of [18F]-DOPA PET/CT studies of 102 patients with biochemical relapse of medullary thyroid carcinoma (54 women and 25 men (68 %:32 %), the median age at the time of the study was 49 years [37;63]). PET/CT acquisition was performed in 15 minutes (early scanning) and 30 minutes (scanning in the standard time point) after intravenous administration of the radiopharmaceutical. The average specific activity of [18F]-DOPA was 3.9 (±0.16) MBq/kg of the patient’s body weight. The presence of foci of pathological accumulation of radiopharmaceutical, their number and localization, and the intensity of accumulation of radiopharmaceutical were determined on PET/CT images performed at different time points.Results. We obtained a statistically significant advantage of early PET/CT scanning in detecting the number of foci of pathological hyperaccumulation of [18F]-DOPA (228 versus 211, p Conclusion. [18F]-DOPA PET/CT should be started 15 minutes after tracer administration to improve topical diagnosis of recurrent medullary thyroid carcinoma due to more intense accumulation of the radiopharmaceutical in the tissue of the recurrent tumor. In addition, early scanning ensures a reduction in radiation exposure to the patient and optimizes the workflow.


  • Open Access

    Diagnostic capabilities of PET/CT with 18F-DOPA in biochemical recurrence of medullary thyroid carcinoma: a retrospective study

    by N. V. Tsentr, A. A. Zyryanova, M. A. Rusnak, D. V. Ryzhkova

    INTRODUCTION: Medullary thyroid carcinoma (MTС) is a rare neuroendocrine malignant neoplasm of the thyroid gland. In most cases, sporadic MTС is diagnosed at late stages due to the absence of specific symptoms. The main method of treatment of MTС is surgical — thyroidectomy and in most cases cervical lymphodissection. Current international guidelines suggest the use of basal calcitonin levels and cancer embryonic antigen (CEA) as markers of biochemical recurrence. In biochemical recurrence of the disease, it is advisable to search for tumor foci regardless of the level of cancer markers. Positron emission tomography combined with computed tomography (PET/CT) has the highest sensitivity and specificity for searching for local recurrence and distant metastases. Anatomical imaging methods (computed tomography (CT), magnetic resonance imaging (MRI)) have suboptimal sensitivity and specificity in detection of a recurrent tumor.OBJECTIVE: To explore the diagnostic capabilities of PET/CT with 18F-DOPA in patients with biochemical recurrence of medullary thyroid carcinoma, depending on the concentration of calcitonin in blood plasma.MATERIALS AND METHODS: To evaluate the diagnostic capabilities of PET/CT with 18F-DOPA in patients with biochemical recurrence of medullary thyroid carcinoma, 81 PET/CT studies were analyzed in patients after thyroidectomy. In most cases (76/81), at the time of the study, patients had elevated basal calcitonin levels (>10 pg/ml, including in 52/81 cases >150 pg/ml), which corresponded to a biochemical recurrence of the disease. In 6 cases, the calcitonin level was 150 pg/ml. A noticeable positive correlation was found between the concentration of basal serum calcitonin, the number of pathological foci of 18F-DOPA hyperaccumulation and the total metabolic volume of tumor tissue. In most cases of biochemical recurrence, the PET method was superior to the CT method in detecting recurrent tumor foci.CONCLUSION: PET/CT with 18F-DOPA is the most informative method for molecular and structural imaging in patients with biochemical recurrence of medullary thyroid carcinoma. The results of the study directly correlate with the level of basal calcitonin in the blood.


  • Open Access

    PET/CT with various radiopharmaceuticals in the complex diagnosis of medullary thyroid carcinoma: a review

    by N. V. Tsentr, A. E. Ertman, D. V. Ryzhkova

    INTRODUCTION: Medullary carcinoma is a rare malignant neuroendocrine tumor of the thyroid gland. Medullary thyroid carcinoma (MTC) has no specific clinical symptoms. Due to the absence of specific symptoms, the disease is usually diagnosed at the stage of metastatic lesions of regional lymph nodes, and sometimes, internal organs. The five- and ten-year survival after detection of distant metastases is 25% and 10%, respectively.OBJECTIVE: To analyze the available foreign and domestic literature to determine the role of PET/CT with various radiopharmaceuticals in the complex radiological diagnosis of MTC.MATERIALS AND METHODS: A search was made for scientific publications and clinical recommendations in the information and analytical systems PudMed, elibrary over the past ten years, dedicated to the diagnosis of MTC, including PET/CT with 18F-DOPA, 18F-FDG, 68Ga-DOTA peptides, etc. by keywords «medullary thyroid cancer», «medullary thyroid carcinoma», «PET/CT», «18F-L-dihydroxyphenylalanine», «18F-DOPA», «18F-DOPA», «68Ga-DOTA peptides», «68Ga-DOTA-peptides», «theranostics», «theranostics».RESULTS: The analysis of publications demonstrated the prospects for the use of PET/CT with various radiopharmaceuticals for the diagnosis of recurrent tumors and the prevalence of the process in biochemical recurrence of MTC, as well as the possibility of peptide-receptor radionuclide therapy for the treatment of advanced forms of the disease. The choice of radiopharmaceuticals is based on the results of laboratory diagnostics and conventional methods of anatomical imaging. PET/CT with 68Ga-DOTA peptides is performed to predict the effectiveness of peptide-receptor radionuclide therapy.CONCLUSION: PET/CT with various radiopharmaceuticals makes a significant contribution to the diagnosis of recurrent tumors, assessment of the prevalence of the tumor process and selection of patients for peptide-receptor radionuclide therapy.


  • Open Access

    Atypical course of Parkinson’s disease with clinical manifestations of Huntington’s disease in a patient with an allele of 27 CAG repeats in the HTT gene

    by M. A. Nikitina, E. Yu. Bragina, M. S. Nazarenko, N. G. Zhukova, D. E. Gomboeva, K. F. Nurzhanova, N. V. Tsentr, V. M. Alifirova

    Атипичное течение болезни Паркинсона с клиническими проявлениями болезни Гентингтона у пациентки с аллелем 27 CAG-повторов в гене HTT